SIREN : 831151501
KLINCARE GROUP is a French company founded 8 years ago, specialized in the sector Gestion de fonds. Based in PARIS (75002), this company of category ETI shows in 2024 a revenue of 5.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 5 701 749 € | 5 026 882 € | 4 378 988 € | 4 157 132 € | 3 312 144 € | 4 119 527 € | 3 847 745 € |
| Net income | 158 364 € | -1 071 868 € | -1 763 537 € | -2 220 699 € | 5 257 057 € | -60 137 470 € | -2 403 952 € |
| EBITDA | 183 508 € | 454 434 € | -120 510 € | -633 349 € | -536 280 € | 490 724 € | -136 323 € |
| Net margin | 2.8% | -21.3% | -40.3% | -53.4% | 158.7% | -1459.8% | -62.5% |
In 2024, KLINCARE GROUP achieves revenue of 5.7 M€. Over the period 2018-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.8%. Vs 2023, growth of +13% (5.0 M€ -> 5.7 M€). After deducting consumption (0 €), gross margin stands at 5.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 184 k€, representing 3.2% of revenue. Warning negative scissor effect: despite revenue change (+13%), EBITDA varies by -60%, reducing margin by 5.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 158 k€, i.e. 2.8% of revenue. This profit can be retained or distributed to shareholders.
5 701 749 €
5 701 749 €
183 508 €
-514 210 €
158 364 €
3.2%
The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 82%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 55.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
9.997%
81.703%
55.03%
1.697
31.0%
In 2024, the debt ratio of KLINCARE GROUP (10.00) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of KLINCARE GROUP (81.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of KLINCARE GROUP (1.70) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 533.91. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 215.0x. Operating income very largely covers interest expenses: high safety margin.
533.908
214.994
In 2024, the liquidity ratio of KLINCARE GROUP (533.91) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of KLINCARE GROUP (215.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 368 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 532 days. Excellent situation: suppliers finance 164 days of the operating cycle (retail model). Overall, WCR represents 1921 days of revenue, i.e. 30.4 M€ to permanently finance. Notable WCR improvement over the period (-39%), freeing up cash.
30 427 098 €
368 j
532 j
0 j
1921 j
Based on 62 transactions of similar company sales
in 2024,
the value of KLINCARE GROUP is estimated at
1 195 021 €
(range 472 807€ - 2 904 624€).
With an EBITDA of 183 508€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.30x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare KLINCARE GROUP with other companies in the same sector:
The revenue of KLINCARE GROUP in 2024 is 5.7 M€.
Yes, KLINCARE GROUP generated a net profit of 158 k€ in 2024.
The headquarters of KLINCARE GROUP is located in PARIS (75002), in the department Paris.
The tax return of KLINCARE GROUP is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
KLINCARE GROUP operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.